{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T12:48:28Z","timestamp":1707223708208},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00108-021-01170-2","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T05:16:51Z","timestamp":1633411011000},"page":"1153-1165","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Niereninsuffizienz im Kontext der kardiopulmorenalen Pathophysiologie"],"prefix":"10.1007","volume":"62","author":[{"given":"Vedat","family":"Schwenger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Insa E.","family":"Emrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Latus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Remppis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"1170_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita\u00a0K et al (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a\u00a0collaborative meta-analysis. Lancet 375:2073\u20132081. https:\/\/doi.org\/10.1016\/S0140-6736(10)60674-5","journal-title":"Lancet"},{"key":"1170_CR2","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMoa041365","volume":"351","author":"NS Anavekar","year":"2004","unstructured":"Anavekar\u00a0NS et\u00a0al (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N\u00a0Engl J Med 351:1285\u20131295","journal-title":"N Engl J Med"},{"key":"1170_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort\u00a0RT et\u00a0al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382:339\u2013352. https:\/\/doi.org\/10.1016\/S0140-6736(13)60595-4","journal-title":"Lancet"},{"key":"1170_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1161\/CIRCHEARTFAILURE.114.001957","volume":"8","author":"A Lala","year":"2015","unstructured":"Lala\u00a0A et al (2015) Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from diuretic optimization strategy evaluation in acute decompensated heart failure (DOSE-AHF) and Cardiorenal rescue study in acute decompensated heart failure (CARESS-HF). Circ Heart Fail 8:741\u2013748. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001957","journal-title":"Circ Heart Fail"},{"key":"1170_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1005419","volume":"364","author":"GM Felker","year":"2011","unstructured":"Felker\u00a0GM et\u00a0al (2011) Diuretic strategies in patients with acute decompensated heart failure. N\u00a0Engl J Med 364:797\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa1005419","journal-title":"N Engl J Med"},{"key":"1170_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jacc.2008.08.080","volume":"53","author":"K Damman","year":"2009","unstructured":"Damman\u00a0K et\u00a0al (2009) Increased central venous pressure is associated with impaired renal function and mortality in a\u00a0broad spectrum of patients with cardiovascular disease. J\u00a0Am Coll Cardiol 53:582\u2013588","journal-title":"J Am Coll Cardiol"},{"key":"1170_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","volume":"53","author":"W Mullens","year":"2009","unstructured":"Mullens\u00a0W et\u00a0al (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J\u00a0Am Coll Cardiol 53:589\u2013596","journal-title":"J Am Coll Cardiol"},{"key":"1170_CR8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2215\/CJN.10191013","volume":"9","author":"SD Navaneethan","year":"2014","unstructured":"Navaneethan\u00a0SD et\u00a0al (2014) Presence and outcomes of kidney disease in patients with pulmonary hypertension. Clin J Am Soc Nephrol 9:855\u2013863. https:\/\/doi.org\/10.2215\/CJN.10191013","journal-title":"Clin J Am Soc Nephrol"},{"key":"1170_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/j.ajkd.2017.11.018","volume":"72","author":"M Tang","year":"2018","unstructured":"Tang\u00a0M et al (2018) Pulmonary hypertension, mortality, and cardiovascular disease in CKD and ESRD patients: a systematic review and meta-analysis. Am J Kidney Dis 72:75\u201383. https:\/\/doi.org\/10.1053\/j.ajkd.2017.11.018","journal-title":"Am J Kidney Dis"},{"key":"1170_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2019.08.027","volume":"75","author":"DL Edmonston","year":"2020","unstructured":"Edmonston\u00a0DL et\u00a0al (2020) Pulmonary hypertension subtypes and mortality in CKD. Am J Kidney Dis 75:713\u2013724. https:\/\/doi.org\/10.1053\/j.ajkd.2019.08.027","journal-title":"Am J Kidney Dis"},{"key":"1170_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/ckj\/sfv007","volume":"8","author":"H Frohlich","year":"2015","unstructured":"Frohlich\u00a0H et al (2015) Peritoneal ultrafiltration in end-stage chronic heart failure. Clin Kidney\u00a0J 8:219\u2013225. https:\/\/doi.org\/10.1093\/ckj\/sfv007","journal-title":"Clin Kidney J"},{"key":"1170_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12882-020-01777-x","volume":"21","author":"L Grossekettler","year":"2020","unstructured":"Grossekettler\u00a0L et\u00a0al (2020) Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients. BMC Nephrol 21:179. https:\/\/doi.org\/10.1186\/s12882-020-01777-x","journal-title":"BMC Nephrol"},{"key":"1170_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/ehf2.12411","volume":"6","author":"L Grossekettler","year":"2019","unstructured":"Grossekettler\u00a0L et\u00a0al (2019) Peritoneal dialysis as therapeutic option in heart failure patients. ESC Heart Fail 6:271\u2013279. https:\/\/doi.org\/10.1002\/ehf2.12411","journal-title":"ESC Heart Fail"},{"key":"1170_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/s-0033-1360037","volume":"139","author":"V Schwenger","year":"2014","unstructured":"Schwenger\u00a0V et al (2014) Dialysis and ultrafiltration therapy in patients with cardio-renal syndrome: recommendations of the working group \u201eheart-kidney\u201c of the German cardiac society and the German society of nephrology. Dtsch Med Wochenschr 139:e1\u20138. https:\/\/doi.org\/10.1055\/s-0033-1360037","journal-title":"Dtsch Med Wochenschr"},{"key":"1170_CR15","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1111\/chf.12030","volume":"19","author":"E Alhaj","year":"2013","unstructured":"Alhaj\u00a0E et\u00a0al (2013) Uremic cardiomyopathy: an underdiagnosed disease. Congest Heart Fail 19:E40\u201345. https:\/\/doi.org\/10.1111\/chf.12030","journal-title":"Congest Heart Fail"},{"key":"1170_CR16","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker\u00a0PM et al (2021) IL\u20116 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a\u00a0double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397:2060\u20132069. https:\/\/doi.org\/10.1016\/S0140-6736(21)00520-1","journal-title":"Lancet"},{"key":"1170_CR17","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.jacc.2020.08.011","volume":"76","author":"BM Everett","year":"2020","unstructured":"Everett\u00a0BM et al (2020) Inhibition of interleukin-1beta and reduction in atherothrombotic cardiovascular events in the CANTOS trial. J\u00a0Am Coll Cardiol 76:1660\u20131670. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.011","journal-title":"J Am Coll Cardiol"},{"key":"1170_CR18","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.kint.2018.10.020","volume":"95","author":"BM Fox","year":"2019","unstructured":"Fox\u00a0BM et\u00a0al (2019) Metabolomics assessment reveals oxidative stress and altered energy production in the heart after ischemic acute kidney injury in mice. Kidney Int 95:590\u2013610. https:\/\/doi.org\/10.1016\/j.kint.2018.10.020","journal-title":"Kidney Int"},{"key":"1170_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2215\/CJN.12591117","volume":"13","author":"AS Go","year":"2018","unstructured":"Go\u00a0AS et\u00a0al (2018) Acute kidney injury and risk of heart failure and atherosclerotic events. Clin J Am Soc Nephrol 13:833\u2013841. https:\/\/doi.org\/10.2215\/CJN.12591117","journal-title":"Clin J Am Soc Nephrol"},{"key":"1170_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1161\/CIRCINTERVENTIONS.112.974493","volume":"6","author":"MT James","year":"2013","unstructured":"James\u00a0MT et al (2013) Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a\u00a0systematic review and meta-analysis. Circ Cardiovasc Interv 6:37\u201343. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.112.974493","journal-title":"Circ Cardiovasc Interv"},{"key":"1170_CR21","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.2215\/CJN.03730411","volume":"6","author":"SD Navaneethan","year":"2011","unstructured":"Navaneethan\u00a0SD et\u00a0al (2011) Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease. Clin J Am Soc Nephrol 6:2395\u20132402. https:\/\/doi.org\/10.2215\/CJN.03730411","journal-title":"Clin J Am Soc Nephrol"},{"key":"1170_CR22","first-page":"S212","volume":"21","author":"M Epstein","year":"2015","unstructured":"Epstein\u00a0M et al (2015) Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 21:S212\u2013220","journal-title":"Am J Manag Care"},{"key":"1170_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","volume":"180","author":"Y Qiao","year":"2020","unstructured":"Qiao\u00a0Y et al (2020) Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med 180:718\u2013726. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0193","journal-title":"JAMA Intern Med"},{"key":"1170_CR24","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/eurheartj\/ehv268","volume":"36","author":"M Edner","year":"2015","unstructured":"Edner\u00a0M, Benson\u00a0L, Dahlstrom\u00a0U, Lund\u00a0LH (2015) Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a\u00a0prospective propensity score-matched cohort study. Eur Heart\u00a0J 36:2318\u20132326. https:\/\/doi.org\/10.1093\/eurheartj\/ehv268","journal-title":"Eur Heart J"},{"key":"1170_CR25","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","volume":"58","author":"SV Badve","year":"2011","unstructured":"Badve\u00a0SV et al (2011) Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a\u00a0systematic review and meta-analysis. J\u00a0Am Coll Cardiol 58:1152\u20131161. https:\/\/doi.org\/10.1016\/j.jacc.2011.04.041","journal-title":"J Am Coll Cardiol"},{"key":"1170_CR26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1681\/ASN.2020050682","volume":"32","author":"EL Fu","year":"2021","unstructured":"Fu\u00a0EL et al (2021) Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study. J\u00a0Am Soc Nephrol 32:424\u2013435. https:\/\/doi.org\/10.1681\/ASN.2020050682","journal-title":"J Am Soc Nephrol"},{"key":"1170_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad\u00a0F et\u00a0al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N\u00a0Engl J Med 364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"1170_CR28","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","volume":"60","author":"O Vardeny","year":"2012","unstructured":"Vardeny\u00a0O et\u00a0al (2012) Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (randomized aldactone evaluation study). J\u00a0Am Coll Cardiol 60:2082\u20132089","journal-title":"J Am Coll Cardiol"},{"key":"1170_CR29","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL et\u00a0al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N\u00a0Engl J Med 383:2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"1170_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.04.079","author":"G Filippatos","year":"2021","unstructured":"Filippatos\u00a0G et\u00a0al (2021) Finerenone reduces onset of atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J\u00a0Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.079","journal-title":"J Am Coll Cardiol"},{"key":"1170_CR31","unstructured":"Pitt B (2021) New Engl J Med 2021, Aug 28, Online ahead of print"},{"key":"1170_CR32","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal\u00a0R et al (2019) Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a\u00a0phase 2, randomised, double-blind, placebo-controlled trial. Lancet 394:1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(19)32135-X","journal-title":"Lancet"},{"key":"1170_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13002","author":"F Spannella","year":"2020","unstructured":"Spannella\u00a0F, Giulietti\u00a0F, Filipponi\u00a0A, Sarzani\u00a0R (2020) Effect of sacubitril\/valsartan on renal function: a\u00a0systematic review and meta-analysis of randomized controlled trials. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.13002","journal-title":"ESC Heart Fail"},{"key":"1170_CR34","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray\u00a0JJ et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med 371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"1170_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez\u00a0EJ et al (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N\u00a0Engl J Med 380:539\u2013548. https:\/\/doi.org\/10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"1170_CR36","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon\u00a0SD et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N\u00a0Engl J Med 381:1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"key":"1170_CR37","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","volume":"138","author":"R Haynes","year":"2018","unstructured":"Haynes\u00a0R et\u00a0al (2018) Effects of sacubitril\/valsartan versus Irbesartan in patients with chronic kidney disease. Circulation 138:1505\u20131514. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034818","journal-title":"Circulation"},{"key":"1170_CR38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","volume":"6","author":"K Damman","year":"2018","unstructured":"Damman\u00a0K et al (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 6:489\u2013498. https:\/\/doi.org\/10.1016\/j.jchf.2018.02.004","journal-title":"JACC Heart Fail"},{"key":"1170_CR39","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/eurheartj\/ehaa968","volume":"42","author":"M Packer","year":"2021","unstructured":"Packer\u00a0M et al (2021) Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a\u00a0reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart\u00a0J 42:671\u2013680. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa968","journal-title":"Eur Heart J"},{"key":"1170_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11560-017-0223-1","volume":"13","author":"V Schwenger","year":"2018","unstructured":"Schwenger\u00a0V, Remppis\u00a0BA (2018) Nephrologische Therapie der schweren Herzinsuffizienz. Nephrologe 13:104\u2013110","journal-title":"Nephrologe"},{"key":"1170_CR41","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMra1703100","volume":"377","author":"DH Ellison","year":"2017","unstructured":"Ellison\u00a0DH, Felker\u00a0GM (2017) Diuretic treatment in heart failure. N\u00a0Engl J Med 377:1964\u20131975. https:\/\/doi.org\/10.1056\/NEJMra1703100","journal-title":"N Engl J Med"},{"key":"1170_CR42","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.114.05122","volume":"65","author":"RH Olde Engberink","year":"2015","unstructured":"Olde Engberink\u00a0RH et al (2015) Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension 65:1033\u20131040. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.05122","journal-title":"Hypertension"},{"key":"1170_CR43","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1161\/HYPERTENSIONAHA.114.05021","volume":"65","author":"GC Roush","year":"2015","unstructured":"Roush\u00a0GC, Ernst\u00a0ME, Kostis\u00a0JB, Tandon\u00a0S, Sica\u00a0DA (2015) Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 65:1041\u20131046. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.05021","journal-title":"Hypertension"},{"key":"1170_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jchf.2019.09.012","volume":"8","author":"ZL Cox","year":"2020","unstructured":"Cox\u00a0ZL, Hung\u00a0R, Lenihan\u00a0DJ, Testani\u00a0JM (2020) Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. JACC Heart Fail 8:157\u2013168. https:\/\/doi.org\/10.1016\/j.jchf.2019.09.012","journal-title":"JACC Heart Fail"},{"key":"1170_CR45","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker\u00a0SD et\u00a0al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N\u00a0Engl J Med 361:2436\u20132448. https:\/\/doi.org\/10.1056\/NEJMoa0908355","journal-title":"N Engl J Med"},{"key":"1170_CR46","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski\u00a0P et al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart\u00a0J 36:657\u2013668. https:\/\/doi.org\/10.1093\/eurheartj\/ehu385","journal-title":"Eur Heart J"},{"key":"1170_CR47","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski\u00a0P et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a\u00a0multicentre, double-blind, randomised, controlled trial. Lancet 396:1895\u20131904. https:\/\/doi.org\/10.1016\/S0140-6736(20)32339-4","journal-title":"Lancet"},{"key":"1170_CR48","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"IC Macdougall","year":"2019","unstructured":"Macdougall\u00a0IC et\u00a0al (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N\u00a0Engl J Med 380:447\u2013458. https:\/\/doi.org\/10.1056\/NEJMoa1810742","journal-title":"N Engl J Med"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01170-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01170-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01170-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T14:02:48Z","timestamp":1635516168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01170-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,4]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01170-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,4]]},"assertion":[{"value":"1 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"V.\u00a0Schwenger, I.E.\u00a0Emrich, F.\u00a0Mahfoud, J.\u00a0Latus und A.\u00a0Remppis geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}